‘IBS and IBD Overlap in Clinical Practice: The Role of the Gut Microbiome and Probiotics’

The human gut microbiota plays a fundamental role in maintaining gastrointestinal health and modulating immune responses. Irritable Bowel Syndrome (IBS) is one of the most common gastrointestinal disorders seen in primary and secondary care with a prevalence rate of up to 20% in the UK population, whereas Inflammatory Bowel Disease (IBD) is less common affecting up to 1% of the UK population. Both conditions can lead to significant disruptions in the gut microbiome composition and function, often resulting in impaired quality of life. IBS and IBD are distinct in their aetiology and manifestation and are multifactorial but do share many common symptoms and characteristics including increased gut permeability, immune dysregulation, inflammation, motility disturbances and changes in the gut microbiota.

Research shows there is a strong overlap of up to 40% of patients with IBD that have reported IBS type symptoms. This has even been seen in those who are in remission of IBD. Those with active IBD are also five times more likely to have symptoms similar to IBS.

This webinar will explore the function of the gut microbiome in IBS and IBD, the impact of microbial dysbiosis and the overlap between both conditions. We will discuss how to classify and manage their symptoms and look at the latest scientific research that addresses specific probiotic strains to reduce and manage the severity of IBS symptoms and manage IBD remission. Probiotic research is emerging as a complementary approach to support remission, reduce inflammatory markers, and improve the mucosal lining.

Sponsored by:

​Click the button below to register for free: